Dazodalibep Drug Asset Due Diligence Report 2026

This Dazodalibep Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 3

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Dazodalibep can convert its Fusion protein profile and CD40L biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Dazodalibep (query alias: dazodalibep)
Modality / target	Fusion protein; CD40L; CD40L inhibitors
Highest global status	Phase 3
Originator	MedImmune LLC
Active developers	Amgen, Inc., The Ohio State University Wexner Medical Center, Horizon Therapeutics Ltd. (Ireland)

The MCP disease footprint includes Sjogren's Syndrome, Lupus Nephritis, Glomerulosclerosis, Focal Segmental. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06747949	Phase 3	Recruiting	844	Number of Participants with Treatment-emergent Adverse Events (TEAEs)
NCT06104124	Phase 3	Active, not recruiting	651	Change from baseline in European Alliance of Associations for Rheumatology Sjögren's Syndrome Disease Activity Index (ESSDAI) Score
NCT05201469	Phase 2	Recruiting	74	Proportion of participants achieving a complete renal response at week 36

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Population Pharmacokinetic/Pharmacodynamic Modeling of Dazodalibep, a CD40L Antagonist, in Healthy Volunteers and Patients with Rheumatoid Arthritis and Sjogren’s Syndrome

Phase 3; n=not disclosed; evaluation: Positive. Reported fields: Chloride = 0.347 L/day

Dazodalibep, a CD40L Antagonist, in Subjects with Sjögren’s Having Moderate-to-Severe Systemic Disease Activity: Full Crossover Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study

Phase 2; n=74; evaluation: Positive. Reported fields: ESSDAI = -6.3 point (SD, 0.6); ESSDAI = -4.1 point (SD, 0.6); ESSDAI = -6.3 point (SD, 0.6)

Dazodalibep, a CD40L Antagonist, in a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Crossover Trial of Subjects with Sjögren’s Disease Having Unacceptable Symptomatic Burden but Limited Extraglandular Organ Involvement

Phase 2; n=109; evaluation: Positive. Reported fields: ESSPRI = −1.3 point (SE, 0.3); ESSPRI = −0.5 point (SE, 0.2); ESSPRI = −1.8 point (SE, 0.3)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Dazodalibep addresses Sjogren's Syndrome, Lupus Nephritis, Glomerulosclerosis, Focal Segmental. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Fusion protein—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2021-02-01	Horizon Therapeutics plc Completes Acquisition of Viela Bio, Inc.	Phase 3	Financial terms not disclosed
2018-02-01	MedImmune spin out six molecules from its early-stage inflammation and autoimmunity programmes into Viela Bio	Phase 1	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “CD40l-specific tn3-derived scaffolds for use in the treatment and prevention of rheumatoid arthritis”. The milestone feed surfaced a patent-application signal described as “CD40l-specific TN3-derived scaffolds for the treatment and prevention of sjogren's syndrome”. The milestone feed surfaced a patent-application signal described as “CD40L特异性TN3衍生支架及其用于治疗和预防类风湿性关节炎的方法”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO